Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
Otto Metzger(Dana-Farber Cancer Institute), Ian E. Krop(Yale Cancer Center), Denise A. Yardley(Sarah Cannon), Aditya Bardia(UCLA Health), Eileen Wrabel(Dana-Farber Cancer Institute), Carlos L. Arteaga(The University of Texas Southwestern Medical Center), Patrizia Dell’Orto(University of Milan), Shayna Stein(Harvard University), Ingrid A. Mayer(Vanderbilt University), Eric P. Winer(University of Vermont), Lorenzo Trippa(Harvard University), Vandana G. Abramson(Vanderbilt University), Tari A. King(Brigham and Women's Hospital), Giuseppe Viale(University of Milan), Adrienne G. Waks(Harvard University), Franziska Michor(Dana-Farber Cancer Institute), Michelle K. DeMeo(Dana-Farber Cancer Institute), Kornélia Polyák(Dana-Farber Cancer Institute), Leila Russo(European Institute of Oncology), Laura M. Spring(Massachusetts General Hospital)
Cited by 241
Related Papers
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
|Nature reviews. Cancer|2009|3.3k
The Genomic Landscapes of Human Breast and Colorectal Cancers
|Science|2007|2.8k
A model for p53-induced apoptosis
|Nature|1997|2.5k